Results 101 to 110 of about 1,190 (173)
Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.Abstract INTRODUCTION An extra copy of the amyloid precursor protein (APP) gene causes autosomal dominant Alzheimer's disease (AD) and AD in Down syndrome (DS), but the factors underlying variability in age at onset (AAO) remain unclear. We investigated whether sporadic AD risk variants modify AAO. METHODS We analyzed clinical and genetic data from 100
Joan Groeneveld +39 more
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.Abstract INTRODUCTION Alzheimer's disease (AD) features amyloid beta (Aβ) plaques and tau tangles, yet how their coexistence reshapes brain transcriptomic programs remains unclear. METHODS We performed high‐quality, sex‐balanced single‐nucleus RNA sequencing of 5XFAD (Aβ), PS19 (tau), and combined 5XFAD;PS19 mice.
Jung Hyun Park +9 more
wiley +1 more source
Brain and Behavior, Volume 16, Issue 8, August 2026.Epigenetic mechanismsincluding DNA methylation, histone modifications, and microRNA (miRNA) regulationmodulate gene expression without altering the DNA sequence and are increasingly implicated in the cognitive impairment associated with Parkinson's disease (PD). Environmental and molecular factors influence these epigenetic pathways, leading to altered
Fatemeh Hasani +10 more
wiley +1 more source
Emerging Trends and Hot Spots in Tauopathy Research (2003–2025): A Bibliometric Analysis
Brain and Behavior, Volume 16, Issue 8, August 2026.This bibliometric analysis systematically evaluated global research trends in tauopathy from 2003 to 2025. Using bibliometric methods, including R package bibliometrix, VOSviewer, and Scimago Graphica, we identified publication trends, influential countries, institutions, authors, journals, and emerging research themes.
Si‐Yao Zhang +4 more
wiley +1 more source
Brain and Behavior, Volume 16, Issue 8, August 2026.The graphical abstract summarizes the current evidence on the potential neuroprotective effects of tirzepatide (TZP), a dual GIP/GLP‐1 receptor agonist, across mechanistic, preclinical, and clinical domains. Mechanistically, TZP is proposed to exert direct neural effects, preserve mitochondrial function, reduce apoptosis, oxidative stress, and ...
Yousef Hawas +6 more
wiley +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.Chronic smoking during adolescence impairs glymphatic transport, leading to cognitive decline and aberrant accumulation of phosphorylated tau in the hippocampal DG region. Smoking‐induced glymphatic dysfunction compromises synaptogenesis and neurogenesis in the hippocampal DG region.
Chuanxiang Lv +11 more
wiley +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.NAP2, a NgR1 antagonist peptide, improved cognition in APP/PS1 mice, reduced Aβ plaques and tau hyperphosphorylation, increased dendritic spine density, and alleviated mitochondrial damage, acting through inhibition of the Nogo‐A/NgR/ROCK pathway, highlighting its therapeutic potential for Alzheimer's disease.
Zheng Zhang +14 more
wiley +1 more source
Multimodel Diffusion MRI Signatures in Atypical Parkinsonian Disorders
Human Brain Mapping, Volume 47, Issue 11, 01 August 2026.We implemented a diffusion MRI framework to analyze clinically compatible multishell data across 123 participants, including controls, Parkinson's disease (PD), corticobasal syndrome (CBS), and progressive supranuclear palsy Richardson's syndrome (PSP‐RS). Diffusion models included DTI, free‐water elimination (FWE), NODDI, and fixel‐based analysis (FBA)
Yuqi Tian +5 more
wiley +1 more source